1 / 3
Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeuticsto address unmet clinical needs in the world.
Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization.
Ribo strives innovation of key technologies for development of oligonucleotide therapeutics. Our liver-targeting delivery technology and second-generation modification chemistry have been fully developed and supported several products entering clinical phase of development. Moreover, we have made substantial advancement in developing extrahepatic delivery technologies, and we also made commendable achievement in additional fronts, including our third-generation modification chemistry, multi-target siRNA technology, and novel synthetic methodologies.
siRNA delivery technology platform
Oligonucleotide modification for enhanced stability platform
CMC Development of Oligonucleotide platform
Oligonucleotide sequence design and high-throughput screening platform
Through our innovation, Ribo has built a robust pipeline of oligonucleotide therapeutics that focus on differentiated drug product development with the potential to be First-In-Class or Best-In-Class. Our pipeline covers multiple therapeutic areas, including cardiovascular and metabolic disorders, liver diseases, rare diseases, and ocular diseases.
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023